{"created":"2023-06-20T12:59:14.610926+00:00","id":962,"links":{},"metadata":{"_buckets":{"deposit":"6b8b2dc2-1986-48c3-a531-185f78be4146"},"_deposit":{"created_by":17,"id":"962","owners":[17],"pid":{"revision_id":0,"type":"depid","value":"962"},"status":"published"},"_oai":{"id":"oai:nufs-nuas.repo.nii.ac.jp:00000962","sets":["122:126:125:99:111"]},"author_link":["312","654","656","559","557","655"],"control_number":"962","item_10002_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2009-03","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3","bibliographicPageEnd":"24","bibliographicPageStart":"17","bibliographic_titles":[{"bibliographic_title":"名古屋学芸大学健康・栄養研究所年報","bibliographic_titleLang":"ja"},{"bibliographic_title":"Annual Report of Institute of Health and Nutrition, Nagoya University of Arts and Sciences","bibliographic_titleLang":"en"}]}]},"item_10002_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"糖尿病患者の薬物による厳密な血糖コントロールは、血糖値の低下と引きかえに体重を増加させることが多い。しかし、この原因は未だに解明されていない。その体重増加の原因の一つとして、安静時エネルギー消費量（REE：resting energy expenditure）が低下していることが考えられる。そこで、2 型糖尿病患者のべ105名を対象として、間接カロリーメーターを用いて REE を測定した。インスリン投与量あるいは経口血糖降下薬服薬量の違いが 2 型糖尿病患者の REE にどのような影響を与えるか比較した。その結果、単一の薬剤を使用している患者のうち、インスリン投与量が多い時に REE は有意に低下したが（p=0.030）、メトフォルミン及びピオグリタゾンの影響は認められなかった。また薬剤を複数併用している患者のうち、インスリン投与量が 8 単位以上の増減がある場合、インスリン投与量が多い時に REE は有意に低下した（p=0.037）。さらに、グリメピリドを 6 mg 以上使用している場合、グリメピリド投与量が多い時に REE は有意に低下した（p=0.029）。これらのことから、2 型糖尿病患者において、インスリン及びグリメピリド療法はREEを低下させ、このことが体重増加の原因であると示唆された。","subitem_description_type":"Abstract"},{"subitem_description":"Intensive diabetes treatment with insulin or hypoglycemic agents often causes body weight gain despite an improvement in blood glucose control, but the reasons are unclear. A decrease in resting energy expenditure (REE) may be one of the causes for weight gain. We measured REE by indirect calorimetry in 105 type 2 diabetic patients and examined whether diabetes treatment with insulin and oral hypoglycemic agents had an influence on REE. Among patients treated with insulin alone or single oral hypoglycemic agents, REE significantly decreased in those administered high-dose insulin (p=0.030), but was not influenced by metformin and pioglitazone. Among patients treated with insulin and/or multiple hypoglycemic agents, REE significantly decreased when the difference in insulin dosage was more than 8 IU (p=0.037) and the glimepride dose was more than 6 mg (p=0.029). These data suggest that diabetes treatment with insulin or glimepride decreased REE and this decrease may be the cause of the weight gain seen in type 2 diabetic patients.","subitem_description_type":"Abstract"}]},"item_10002_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"名古屋学芸大学健康・栄養研究所","subitem_publisher_language":"ja"}]},"item_10002_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"名古屋学芸大学健康・栄養研究所"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://www.nuas.ac.jp/IHN/index.html","subitem_relation_type_select":"URI"}}]},"item_10002_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"18821820","subitem_source_identifier_type":"PISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorAffiliations":[{"affiliationNameIdentifiers":[{"affiliationNameIdentifierScheme":"ISNI","affiliationNameIdentifierURI":"http://www.isni.org/isni/"}],"affiliationNames":[{"affiliationNameLang":"ja"}]}],"creatorNames":[{"creatorName":"Tsukahara, Takayoshi","creatorNameLang":"en"},{"creatorName":"塚原, 丘美","creatorNameLang":"ja"},{"creatorName":"ツカハラ, タカヨシ","creatorNameLang":"ja-Kana"}],"familyNames":[{},{},{}],"givenNames":[{},{},{}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"四本, 礼子","creatorNameLang":"ja"},{"creatorName":"ヨツモト, レイコ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"寺田, 桜子","creatorNameLang":"ja"},{"creatorName":"テラダ, ヨウコ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"姉崎, 恭子","creatorNameLang":"ja"},{"creatorName":"アネサキ, キョウコ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorAffiliations":[{"affiliationNameIdentifiers":[{"affiliationNameIdentifier":"","affiliationNameIdentifierScheme":"ISNI","affiliationNameIdentifierURI":"http://www.isni.org/isni/"}],"affiliationNames":[{"affiliationName":"","affiliationNameLang":"ja"}]}],"creatorNames":[{"creatorName":"岡田, 巳紀","creatorNameLang":"ja"},{"creatorName":"オカダ, ミキ","creatorNameLang":"ja-Kana"}],"familyNames":[{},{}],"givenNames":[{},{}],"nameIdentifiers":[{}]},{"creatorAffiliations":[{"affiliationNameIdentifiers":[{"affiliationNameIdentifier":"","affiliationNameIdentifierScheme":"ISNI","affiliationNameIdentifierURI":"http://www.isni.org/isni/"}],"affiliationNames":[{"affiliationName":"","affiliationNameLang":"ja"}]}],"creatorNames":[{"creatorName":"渡邊, 源市","creatorNameLang":"ja"},{"creatorName":"ワタナベ, ゲンイチ","creatorNameLang":"ja-Kana"}],"familyNames":[{},{}],"givenNames":[{},{}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2016-06-20"}],"displaytype":"detail","filename":"ihn03_03.pdf","filesize":[{"value":"773.7 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"本文","url":"https://nufs-nuas.repo.nii.ac.jp/record/962/files/ihn03_03.pdf"},"version_id":"f8018fe3-b52b-4f24-97f7-52216e6cadfa"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"安静時エネルギー消費","subitem_subject_scheme":"Other"},{"subitem_subject":"インスリン","subitem_subject_scheme":"Other"},{"subitem_subject":"グリメピリド","subitem_subject_scheme":"Other"},{"subitem_subject":"メトフォルミン","subitem_subject_scheme":"Other"},{"subitem_subject":"2型糖尿病","subitem_subject_scheme":"Other"},{"subitem_subject":"resting energy expenditure","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"insulin","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"glimepride","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"metformin","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"type 2 diabetes","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"2型糖尿病患者におけるインスリン及びグリメピリド療法は安静時エネルギー消費量を低下させる","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"2型糖尿病患者におけるインスリン及びグリメピリド療法は安静時エネルギー消費量を低下させる","subitem_title_language":"ja"},{"subitem_title":"Insulin and glimepride therapy decrease resting energy expenditure in type 2 diabetic patients","subitem_title_language":"en"}]},"item_type_id":"10002","owner":"17","path":["111"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2016-06-20"},"publish_date":"2016-06-20","publish_status":"0","recid":"962","relation_version_is_last":true,"title":["2型糖尿病患者におけるインスリン及びグリメピリド療法は安静時エネルギー消費量を低下させる"],"weko_creator_id":"17","weko_shared_id":-1},"updated":"2023-10-16T05:45:35.522119+00:00"}